title: [Immunohistochemical study of the predictive value of oncoproteins p53, HER-2 and c-myc during radiotherapy for squamous cell carcinoma of the cervix].
abstract: Out of 80 patients with squamous cell cervical carcinoma (stage II-III), p53 expression was observed in 30% of tumors prior to treatment and 49% in the course of radiotherapy. A correlation between degree of p53 expression before treatment, on the one hand, and overall and recurrence-free survival, on the other, was identified: high expression of mutated gene-suppressor p53 was 53% while for absence or low expression, it rose to 67% (p=0.03). For overexpression, 20-month survival was 65%; absence--81% (p=0.01). Hence, p53 expression may be used as a predictive factor in radiotherapy for cervical carcinoma. No correlation was found between p53 expression, on the one hand, and such basal clinico-morphological parameters as stage, morphological pattern and tumor cell differentiation, on the other. HER2(3t) overexpression occurred in 2 (2.5%) which seems to point to its insignificant role in squamous cell cervical carcinoma. There was no relationship between c-myc expression and long-term results.
authors.forename: N A
authors.initials: NA
authors.lastname: Gasparian
authors.forename: K M
authors.initials: KM
authors.lastname: Pozharisskiĭ
authors.forename: G M
authors.initials: GM
authors.lastname: Zharinov
authors.forename: V L
authors.initials: VL
authors.lastname: Vinokurov
authors.forename: M E
authors.initials: ME
authors.lastname: Kuznetsova
authors.forename: N Iu
authors.initials: NIu
authors.lastname: Neklasova
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000378:metabolism*; D002294:Carcinoma, Squamous Cell / Q000378:metabolism / Q000473:pathology / Q000532:radiotherapy*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D016271:Proto-Oncogene Proteins c-myc / Q000378:metabolism*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D016019:Survival Analysis; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism*; D015854:Up-Regulation / Q000528:radiation effects; D002583:Uterine Cervical Neoplasms / Q000378:metabolism / Q000473:pathology / Q000532:radiotherapy*
chemical_list: D014408:Biomarkers, Tumor; D016271:Proto-Oncogene Proteins c-myc; D018719:Erb-b2 Receptor Tyrosine Kinases; D016159:Tumor Suppressor Protein p53